SANUWAVE Health Submits Final Module of PMA Application for FDA Approval of dermaPACE to Treat Diabetic Foot Ulcers

ALPHARETTA, Ga.--(BUSINESS WIRE)--SANUWAVE Health, Inc. (OTCBB: SNWV) (www.sanuwave.com), an emerging medical technology company focused on the development and commercialization of noninvasive, biological response activating devices in regenerative medicine, today announced that it has submitted to the U.S. Food and Drug Administration (FDA) the third and final module of its Premarket Approval (PMA) application for the dermaPACE® device for the treatment of diabetic foot ulcers (DFU).